2026
Patent
European and Canadian patents granted
Savicell expanded its international patent portfolio with European Patent No. 3673267 and Canadian Patent No. 3,073,254.
NEWS & MILESTONES
Progress across science, clinical development, patents and partnerships.
This archive migrates the dated updates published on Savicell’s legacy Latest News page into the new website design.
2025
Patent
New U.S. continuation and Israel patents granted
Savicell received U.S. continuation Patent No. 12,306,188 and Israel Patent No. 272810, further strengthening the company’s intellectual-property portfolio.
Patent portfolio
Patents
Previously granted patents across key markets
Previously granted patents include U.S. No. 11,619,634; Japan No. 7356412; Mexico No. 418741; Australia No. 2018320264; and Korea No. 10-2735890.
January 2025
Patent
USPTO Notice of Allowance
The United States Patent and Trademark Office issued a Notice of Allowance for Savicell’s continuation patent application, “Methods of Diagnosing and Treating Lung Cancer.” The continuation builds on U.S. Patent No. 11,619,634 B2 and expands IP protection around lung-cancer diagnostics and liquid biopsy.
October 2024
Patent
Notice of Allowance in Mexico
The Mexican Divisional Directorate of Patents issued a Notice of Allowance for “Methods of Diagnosing and Treating Lung Cancer.”
August 2024
Patent
Notice of Allowance in Korea
The Korean Intellectual Property Office issued a Notice of Allowance for “Methods of Diagnosing and Treating Lung Cancer.”
July 2024
Patent
Patent acceptance in Australia
The Australian Patent Office issued a Notice of Acceptance for “Methods of Diagnosing and Treating Lung Cancer.”
March 2024
Advisory Board
Prof. Aaron Ciechanover joins Savicell’s Advisory Board
Prof. Aaron Ciechanover, Distinguished Research Professor at the Technion and the 2004 Nobel laureate in Chemistry, joined Savicell’s Advisory Board. His scientific career includes foundational work on ubiquitin-mediated protein degradation and leadership roles across major Technion research centers.
September 2023
Publication
Case report on early-stage lung-cancer detection
A case report describing Liquid ImmunoBiopsy-based detection of early-stage lung cancer in a volunteer recruited as a healthy donor was published in the Open Journal of Clinical & Medical Case Reports.
Open source →September 2023
Patent
Japan patent granted
The Japan Patent Office granted a patent titled “Methods of Diagnosing and Treating Lung Cancer.”
April 2023
Patent
U.S. patent granted
The USPTO granted a patent titled “Methods of Diagnosing and Treating Lung Cancer.”
February 2023
Publication
Lung-cancer clinical study published in Respiratory Research
Savicell’s lung-cancer clinical study results were published in the peer-reviewed journal Respiratory Research.
Open source →October 2022
Patent
USPTO Notice of Allowance
The USPTO issued a Notice of Allowance on a patent application titled “Methods of Diagnosing and Treating Lung Cancer,” further building Savicell’s U.S. patent estate.
July 2022
Intellectual Property
Freedom-to-operate opinion received
Savicell reported receipt of a clean patent freedom-to-operate opinion, intended to reduce IP-related commercialization risk.
July 2022
Patent
Brazil patent allowance
The Brazilian Patent Office allowed Savicell’s patent covering methods for measuring cell metabolic activity, diagnosing disease associated with modified metabolic activity, optimizing and monitoring treatment, and identifying agents capable of altering cellular metabolic activity.
September 2021
Clinical
Improved lung-cancer protocol reported
In a clinical trial of 245 participants, Savicell reported that an improved test protocol increased accuracy, with specificity reported at 97% and Stage I lung-cancer sensitivity reported at 97%. The legacy news page refers readers to the publication section for study details.
August 2021
Collaboration
Collaboration with Orgenesis Inc.
Savicell finalized a collaboration agreement with Orgenesis Inc. to use Savicell’s patented immunometabolism platform in development and validation of QC and/or monitoring kits for cell and gene therapy manufacturing and processing.
October 2020
Clinical Study
SARS-CoV-2 T-cell reactivity study initiated
Savicell initiated a clinical study using the ImmunoBiopsy™ platform to evaluate T-cell reactivity to SARS-CoV-2.
Open source →December 2019
Advisory Board
Peter C. Gonze appointed to Advisory Board
Peter C. Gonze joined Savicell’s Advisory Board, bringing more than 40 years of healthcare leadership across diagnostics, biotechnology, immunotherapeutics and clinical research organizations.
September 2018
Clinical
ERS poster presentation on early-stage lung-cancer study
Savicell announced a poster presentation of clinical results from an early-stage lung-cancer study using ImmunoBiopsy™ at the International Congress of the European Respiratory Society.
May 2018
Publication
Clinical study published in Cancer Immunology, Immunotherapy
Savicell’s lung-cancer clinical study results were published as an original article in Cancer Immunology, Immunotherapy.
Open source →September 2016
Patents / Platform
Asian patents and early platform results
Savicell reported patent approvals in China and Japan for methods of monitoring and analyzing metabolic activity profiles and described the platform as a broad blood-based ImmunoBiopsy™ technology with potential applications across cancer, autoimmune and infectious diseases. The update also described early lung- and breast-cancer work and the company’s decision to focus resources on lung cancer as the lead product.
December 16, 2015
Clinical / Company
Rambam ethics approval and expanded Haifa laboratory
Savicell reported ethics-committee approval at Rambam Health Care Campus to conduct clinical trials on human blood for its lung-cancer early-diagnosis test, alongside a move to a larger customized laboratory in Haifa designed to support increased testing and analysis volume.